Tabet I, Candiello E, Fenou L, Velazquez C, Jacot W, Ribeyre C, Sardet C, Theillet C Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe.. Cancer Research. 2025;in press.
Di Michele M, Attina A, Roux P-F, Laguesse S, Florido J, Houdeville M, Choquet A, Encislai B, Arena G, De Blasio C, Wendling O, Frenois F-X, Papon L, Stuani L, Fuentes M, Jahannault Talignani C, Rousseau M, Guégan J, Buscail Y, Dupré P, Michaud H-A, Rodier G, Bellvert F, Kulyk H, Ferraro Peyret C, Mathieu H, Close P, Rapino F, Chaveroux C, Pirot N, Rubio L, Torro A, Sorg T, Ango F, Hirtz C, Compan V, Lebigot E, Legati A, Ghezzi D, Nguyen L, David A, Sardet C, Lacroix M, Le Cam L E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development. Nat Commun. 2025;16(1):67. doi:10.1038/s41467-024-55444-y
Slaninová V, Heron-Milhavet L, Robin M, Jeanson L, Aissanou A, Kantar D, Tosi D, Bréhélin L, Gongora C, Djiane A The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC Cancer. 2024;24(1):587. doi:10.1186/s12885-024-12316-4
Bruciamacchie M, Garambois V, Vie N, Bessede T, Michaud H-A, Gros L, Bonnefoy N, Robin M, Brager D, Bigot K, Evrard A, Pourquier P, Colinge J, Mathonnet M, Belhabib I, Jean C, Bousquet C, Colombo P-E, Jarlier M, Gongora C, Larbouret C ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. Br J Cancer. 2024-11-29. doi:10.1038/s41416-024-02904-3
Desroys du Roure P, Lajoie L, Mallavialle A, Alcaraz L, Mansouri H, Fenou L, Garambois V, Rubio L, David T, Coenon L, Boissière-Michot F, Chateau M-C, Ngo G, Jarlier M, Villalba M, Martineau P, Laurent-Matha V, Roger P, Guiu S, Chardès T, Gros L, Liaudet-Coopman E A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer. J Immunother Cancer. 2024;12(1):e007135. doi:10.1136/jitc-2023-007135
Manteaux G, Amsel A, Riquier-Morcant B, Prieto Romero J, Gayte L, Fourneaux B, Larroque M, Gruel N, Quignot C, Jacq S, Pomiès P, Sengenes C, Chibon F, Heuillet M, Bellvert F, Watson S, Firmin N, Riscal R, Linares L A metabolic crosstalk between liposarcoma and muscle sustains tumor growth. Nat Commun. 2024;15(1):7940. doi:10.1038/s41467-024-51827-3
Villemin J-P, Bassaganyas L, Pourquier D, Boissière F, Cabello-Aguilar S, Crapez E, Tanos R, Cornillot E, Turtoi A, Colinge J Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR. Nucleic Acids Res. 2023-05-05. doi:10.1093/nar/gkad352
Jacquier V, Gitenay D, Fritsch S, Bonnet S, Gy?rffy B, Jalaguier S, Linares L, Cavaillès V, Teyssier C RIP140 inhibits glycolysis-dependent proliferation of breast cancer cells by regulating GLUT3 expression through transcriptional crosstalk between hypoxia induced factor and p53. Cell Mol Life Sci. 2022;79(5):270. doi:10.1007/s00018-022-04277-3
Pisareva E, Mihalovi?ová L, Pastor B, Kudriavtsev A, Mirandola A, Mazard T, Maus U, Ostermann L, Weinmann-Menke J, Neuberger E, Simon P, Thierry A Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA. Genome Med. 2022;14(1):135. doi:10.1186/s13073-022-01125-8
du Manoir S, Delpech H, Orsetti B, Jacot W, Pirot N, Noel J, Colombo P-E, Sardet C, Theillet C In high-grade ovarian carcinoma, platinum-sensitive tumor recurrence and acquired-resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. J Pathol. 2022;257(3):367-378. doi:10.1002/path.5896
Chiavarina B, Costanza B, Ronca R, Blomme A, Rezzola S, Chiodelli P, Giguelay A, Belthier G, Doumont G, Van Simaeys G, Lacroix S, Yokobori T, Erkhem-Ochir B, Balaguer P, Fabbrizio E, Di Valentin E, Detry O, Jerusalem G, Goldman S, Delvenne P, Bellahcène A, Pannequin J, Castronovo V, Turtoi A Metastatic colorectal cancer cells maintain the TGF? program and use TGFBI to fuel angiogenesis. Theranostics. 2021;11(4):1626-1640. doi:10.7150/thno.51507
Relier S, Ripoll J, Guillorit H, Amalric A, Achour C, Boissière F, Vialaret J, Attina A, Debart F, Choquet A, Macari F, Marchand V, Motorin Y, Samalin E, Vasseur J-J, Pannequin J, Aguilo F, Lopez-Crapez E, Hirtz C, Rivals E, Bastide A, David A FTO-mediated cytoplasmic m6Am demethylation adjusts stem-like properties in colorectal cancer cell. 2021-03-20 00:00:00. doi:10.1038/s41467-021-21758-4
Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, Mollevi C, Boissière-Michot F, Huesgen P, Overall C, Tartare-Deckert S, Jacot W, Chardès T, Guiu S, Roger P, Reinheckel T, Moali C, Liaudet-Coopman E A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021;11(13):6173-6192. doi:10.7150/thno.58254
Pichard A, Marcatili S, Karam J, Constanzo J, Ladjohounlou R, Courteau A, Jarlier M, Bonnefoy N, Patzke S, Stenberg V, Coopman P, Cartron G, Navarro-Teulon I, Repetto-Llamazares A, Heyerdahl H, Dahle J, Bardiès M, Pouget J-P The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest. Leukemia. 2020;34(5):1315-1328. doi:10.1038/s41375-019-0677-4
Alame M, Cornillot E, Cacheux V, Tosato G, Four M, Oliveira L, Gofflot S, Delvenne P, Turtoi E, Cabello-Aguilar S, Nishiyama M, Turtoi A, Martineau V, Colinge J The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. Theranostics. 2020;10(10):4383-4394. doi:10.7150/thno.42986
Cissé M, Pyrdziak S, Firmin N, Gayte L, Heuillet M, Bellvert F, Fuentes M, Delpech H, Riscal R, Arena G, Chibon F, Le Gellec S, Maran-Gonzalez A, Chateau M-C, Theillet C, Portais J-C, Le Cam L, Linares L Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci Transl Med. 2020;12(547):eaay2163. doi:10.1126/scitranslmed.aay2163
Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Landas E, Bleuse J-P, Chardès T, Prost J-F, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples. Br J Cancer. 2020;122(3):397-404. doi:10.1038/s41416-019-0670-8
Hamyeh M, Bernex F, Larive R, Naldi A, Urbach S, Simony-Lafontaine J, Puech C, Bakhache W, Coopman P, Hendriks W, Freiss G PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics. 2020;10(3):1016-1032. doi:10.7150/thno.38537
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. J Clin Invest. 2020;130(2):612-624. doi:10.1172/JCI126896
Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z
Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091
Constanzo J, Parach A, David T, Karam J, Bruchertseifer F, Morgenstern A, Jarlier M, Bardiès M, Deshayes E, Gudin-de-vallerin A, Boissière-Michot F, Lopez-Crapez E, Pouget J-P MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy. in press.
Institut de Recherche en Cancérologie de
